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Abstract
In recent years emerging markets such as India, China, and Brazil have developed appropriate business models and
lower-cost technological innovations to address health challenges locally and internationally. But it is not well
understood what capabilities African countries, with their high disease burden, have in science-based health
innovation.
This gap in knowledge is addressed by this series in BMC International Health and Human Rights. The series pre-
sents the results of extensive on-the-ground research in the form of four country case studies of health and
biotechnology innovation, six studies of institutions within Africa involved in health product development, and one
study of health venture funds in Africa. To the best of our knowledge it is the first extensive collection of empirical
work on African science-based health innovation.
The four country cases are Ghana, Rwanda, Tanzania and Uganda. The six case studies of institutions are A to Z Textiles
(Tanzania), Acorn Technologies (South Africa), Bioventures venture capital fund (South Africa), the Malagasy Institute of
Applied Research (IMRA; Madagascar), the Kenyan Medical Research Institute (KEMRI; Kenya), and Niprisan’sd e v e l o p -
ment by Nigeria’s National Institute for Pharmaceutical Research and Development and Xechem (Nigeria).
All of the examples highlight pioneering attempts to build technological capacity, create economic opportunities,
and retain talent on a continent significantly affected by brain drain. They point to the practical challenges for
innovators on the ground, and suggest potentially helpful policies, funding streams, and other support systems.
For African nations, health innovation represents an opportunity to increase domestic capacity to solve health chal-
lenges; for international funders, it is an opportunity to move beyond foreign aid and dependency. The shared
goal is creating self-sustaining innovation that has both health and development impacts. While this is a long-term
strategy, this series shows the potential of African-led innovation, and indicates how it might balance realism
against opportunity. There is ample scope to learn lessons more systematically from cases like those we discuss; to
link entrepreneurs, scientists, funders, and policy-makers into a network to share opportunities and challenges; and
ultimately to better support and stimulate African-led health innovation.
Introduction
Innovations in health technologies, including advance-
ments in biotechnology, have led to vast health improve-
ments in the developed world [1]. The development and
commercialization of new drugs, vaccines, diagnostics,
and other health technologies for the wealthier parts of
the world command sizeable investment every year [2-4].
In contrast, innovation in life sciences for diseases
affecting people living in the developing world has
historically been low [5]. Despite the vast health and eco-
nomic burden associated with disease in developing
countries, particularly in sub-Saharan Africa, developed
world companies have not generally ventured to address
them. Historically, demand and distribution mechanisms
were poorly understood, potential profits perceived to be
low, and overall risk considered to outweigh reward [6].
Over the last decade, a number of initiatives have
emerged to address these issues including Advance Mar-
ket Commitments, product development partnerships,
patent pools, and prizes to reward innovation. The num-
ber of drugs in development for neglected diseases has
increased [7], and funding for research and development
(R&D) for neglected diseases has increased significantly.
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with HIV/AIDS, malaria and tuberculosis initiatives com-
prising close to three-quarters of this investment [8].
While these new research and funding initiatives are
welcome, they are mainly concerned with creating incen-
tives for innovation within developed country institutions.
Questions remain about ongoing costs and sustainability
of neglected disease R&D [9], and the capacity for devel-
oping countries, particularly in Africa, to absorb new tech-
nologies within local contexts.
In recent years we have seen how emerging markets
such as India, China, and Brazil are developing appro-
priate business models and lower-cost technological
innovations to address health challenges locally and
internationally [10-13]. Indeed, recent reports indicate
that for some diseases, traditional donor funding is
increasingly being supplemented by investment from
these emerging economies [8].
A missing piece of the global health R&D puzzle is
understanding what capabilities African countries them-
selves have in science-based health innovation – in inter-
nalizing foreign health innovations, and especially in
developing their own home-grown ideas and translating
these into products and services. The contribution of
African countries to health innovation for their own
needs is not well-documented or understood. Nor is
involvement in local health product development purely
a health issue: as African countries attempt to diversify
their economies, it will be a high priority to build science,
technology and innovation capacity and stimulate an
entrepreneurial culture responsive to local needs [14,15].
Without indigenous capacity in innovation—be it R&D
infrastructure, trained personnel, funding for the devel-
opment and translation of new ideas, or the presence of
firms that can participate in product development and
delivery—it is hard to imagine that foreign technologies,
however much needed, can be sustainably or affordably
absorbed or utilized, or that indigenous technologies can
be fostered for local use.
A series of efforts have been made over the last few
years to build commitment at the policy level and mobi-
lize resources towards home-grown African health inno-
vation. These include the New Economic Partnership
for African Development (NEPAD) Consolidated S&T
Action Plan [16], which outlines key technology plat-
forms for the continent, and the NEPAD/African Union
report on Science, Technology and Innovation for Pub-
lic Health in Africa, which comprehensively makes the
case for health innovation systems and highlights the
necessary changes in policy thinking which will be
needed to tie health goals to economic ones [17]. The
High-Level African Panel on Modern Biotechnology
report, Freedom to Innovate [18], which reported to the
African Union, also addressed health biotechnology and
made recommendations for a more integrated approach
to regulation, research, and intellectual property protec-
tion across the continent. More recently, the African
Network for Drugs and Diagnostics Innovation (ANDI),
which aims to coordinate existing R&D in Africa
towards addressing public health needs, is an example
of how African stakeholders are taking leadership in
managing and strengthening their own health innova-
tion agenda [19].
This series in BioMed Central’sj o u r n a lBMC Interna-
tional Health and Human Rights adds to these efforts by
filling the gap in knowledge around Africa’sc a p a c i t yf o r
science-based health innovation, including biotechnology.
By “science-based health innovation”, we mean technolo-
gical innovation across a spectrum of sophistication,
from vaccines, pharmaceuticals, and medical devices, to
some plant medicines where attempts to scientifically
standardize or characterize medicines have been made.
We take a broad definition of innovation to refer not
only to ‘new to the world’ technologies but also to the
diffusion, adaptation and use of technologies [20]. We
also use the OECD definition of biotechnology: “the
application of science and technology to living organisms,
as well as parts, products and models thereof, to alter
living or non-living materials for the production of
knowledge, goods and services” [21].
This series presents the results of extensive on-the-
ground research in the form of four country case studies
of health and biotechnology innovation, six studies of
institutions within Africa involved in health product
development, and one study of health venture funds in
Africa. To the best of our knowledge it is the first
extensive collection of empirical work on African
science-based health innovation.
The articles are arranged with the country papers com-
ing first to give overall context, followed by the institu-
tional papers. The four country cases are Ghana,
Rwanda, Tanzania and Uganda. These countries were
chosen for a variety of reasons: their relatively high GDP
among the larger sub-Saharan African countries and, for
the most part, stable governance situations; the presence
of established health research institutes; and government
policies supporting science for economic and social
gains. The researchers also had invitations from govern-
ment representatives to undertake studies.
The six case studies of institutions involved in health
technology development are A to Z Textiles (Tanzania),
Acorn Technologies (South Africa), Bioventures venture
capital fund (South Africa), the Malagasy Institute of
Applied Research (IMRA; Madagascar), the Kenyan Med-
ical Research Institute (KEMRI; Kenya), and Niprisan’s
development by Nigeria’s National Institute for Pharma-
ceutical Research and Development and Xechem
(Nigeria). These case studies of institutions and products
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and different types of institutions. They represent initia-
tives that have each achieved success in developing health
solutions, albeit accompanied by important challenges
and shortcomings. Together, the six institutional cases
shed light on the dynamics and challenges at the level of
individual institutions involved in African health innova-
tion. Very often, these are shaped by the overall environ-
ment for innovation in the country; as such, the country
papers provide context for the institutional papers, which
in turn illustrate specific issues raised in the country
papers. Each institutional paper also highlights one or
more general policy questions facing those who would
develop policy for, take part in, or invest in African-led
health innovation.
South Africa is excluded from our country analysis
because it is considerably more technologically advanced
in health and biotechnology innovation than the rest of
Sub-Saharan Africa, and because it has already been
extensively reported upon elsewhere [22]. However, we
include two institutional cases from South Africa
(Acorn Technologies and Bioventures venture capital
fund) as local pioneering examples of a life sciences
incubator and fund respectively. Such incubators and
funds are still nascent in the rest of sub-Saharan Africa,
but are being actively explored, and we believe Acorn
and Bioventures hold important lessons and cautionary
notes for other sub-Saharan African countries.
We expect the collective results of this study to be of
interest to a wide range of stakeholders including
domestic governments; donor agencies; regional and
international organizations seeking to promote science,
technology and innovation in Africa; companies and
researchers looking for partners; and those interested in
investing in Africa.
Methodology
Our conceptual framework for these studies is that of
the ‘innovation system’, which holds that innovation is
not a solitary or linear process, but rather involves
learning and knowledge flow across a diverse network of
stakeholders – firms, government departments, universi-
ties, non-governmental organizations, and end users
[23,24]. As such, it focuses on interactions between
groups, and the role of institutions and policy frame-
works in enabling systemic performance. We recognize
that the framework can only be taken as a guide when
applied in the African context, and therefore have let
the empirical data guide fieldwork and data analysis.
Our country and institutional case studies combine
qualitative and quantitative data and use case study
methodology. Data were collected through semi-struc-
tured face-to-face interviews with members of the public
sector, R&D organizations, academia, government
agencies, private sector enterprises, NGOs and funding
agencies, supplemented with analyses of background
documents and with observations. All quotes are from
the interviews unless otherwise noted, and with permis-
sion. These studies were approved by the Office of
Research Ethics of the University of Toronto.
Summary of findings
Although differences exist across the countries in their
environments for science-based health innovation—such
as varying levels of scientific infrastructure, diverse pol-
icy instruments, and different levels of human resource
development—in general, the core dynamics of innova-
tion and challenges faced were similar. Likewise, the
institutional cases, despite being drawn from a broad
spectrum of countries and project types, suggest com-
mon themes. Below, we summarize key findings from
our research.
Despite challenges, components of health innovation
exist
Our research finds a range of issues, generally common
across all countries, that affect capacity for science-based
health innovation. These include low levels of human
resources with the skills to engage in research; low
investment in scientific infrastructure and R&D (only
Rwanda has an R&D investment over 1% GDP; Tanzania
has recently pledged to raise its R&D investment to 1% of
GDP as of 2009/2010); a research-focused public sector
with weak ties to industry; little or no incentives for firms
to innovate in the health area; and a lack of policy coher-
ence so far on the use of science and technology (S&T)
f o rd e v e l o p m e n t .H o w e v e r ,w ea l s of o u n da r e a so fi n s t i -
tutional and research strength in each country, such as a
wealth of experience in plant medicine, small entrepre-
neurial firms, regulatory expertise, government innova-
tion funds, and scientists involved in well-regarded
international research. Furthermore, as discussed in more
detail in the country papers, country policies are gradu-
ally evolving towards incorporating innovation as well as
S&T – Rwanda’s is focused on mobilizing its growing
skilled population around key economic areas, and Gha-
na’s recently-published STI policy explicitly addresses
innovation [25].
Though limited, diverse activity in health innovation is
occurring
All the countries we studied possess some examples of
health innovation, generally in small, entrepreneurial
firms. Activities include the production of essential medi-
cines, such as anti-retrovirals, through technology trans-
fer generally from other Southern firms; incremental
innovations in making products better adapted to local
conditions such as DanAdams’ pediatric anti-malarial
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tries’s Homapack product for home-based management
of children’s fever (Uganda). One firm – Ghana’s LaGray
Pharmaceuticals – has the more advanced technological
capabilities to produce the raw materials that go into
drugs (Active Pharmaceutical Ingredients) and is the only
such manufacturer in Sub-Saharan Africa outside of
South Africa. Some capacitye x i s t si nd i a g n o s t i c s ,
and some in medical devices, such as A to Z (Tanzania),
Africa’s largest bed-net manufacturer. Finally, we identify
institutions and firms bringing scientific rigor to the
commercialization of plant medicines. In general, strong
entrepreneurial drive, a good understanding of local
demand and, in most cases, a connection into interna-
tional networks to access technology, funding or markets
has been behind the success of these firms. However,
local connections to other firms or to research institu-
tions are weak, and most firms work in relative isolation.
Despite the relatively large amount of health research,
very little has resulted in new products or technologies
to address local disease
All countries had one or more public sector research
facilities or universities regarded as national leaders in
health research. These were heavily supported by interna-
tional funding, and networked into a range of interna-
tional universities, donors and non-governmental
organizations supporting health research. However most
projects were at the basic or at best applied research
level, and not concerned with the generation of local
intellectual property or organizations to take new health
solutions to scale. Where health research capacity is
directed towards product development, it is usually
through participation in clinical trials. As such, we found
a range of ideas for, and sometimes even prototypes of,
locally-relevant, health-focused technologies, which had
stagnated within institutions which lacked the capacity to
evaluate or further develop them. Examples include diag-
nostic tools such as Hepcell, a diagnostic kit for detecting
human hepatitis B surface antigen (KEMRI, Kenya) and a
rapid diagnostic test for schistosomiasis (Noguchi Insti-
tute, Ghana), as well as a wide variety of plant-based
remedies at various stages of development. See Table 1
for a list of prospective technologies suitable for licensing
and potential further development. Our case study of
Kenya’s KEMRI demonstrates that an institution can be
successful in doing research and building a network of
international partnerships, but still struggle to turn its
research into health solutions or technologies. Reasons
for this are many, and include incentive structures within
public research institutions, a skepticism towards com-
mercial applications of knowledge, and the fact that
health research can be driven by donor priorities and
timelines rather than local ones. This is demonstrated by
a lack of demand from end-users, particularly the local
private sector, for the type of health research being
conducted.
All countries put strong emphasis on plant medicine
as a local asset for innovation
Every country has institutions responsible for scientific
research into plant medicines and cites plant medicine as
a primary asset for African countries to enter ‘world first’
innovative activity in health product development. How-
ever, despite the enthusiasm for developing plant medi-
cines to higher scientific standards, progress has been slow
and the necessary coordination across groups absent. This
signals the challenging nature of the field, where the com-
munal aspect of knowledge ownership, variety of stake-
holders involved, and lack of scientific infrastructure
all play a part. A partial exception is Nigeria’s anti sickle
cell drug Niprisan, whose development from a traditional
medicine concoction was spearheaded by its National
Institute for Pharmaceutical Research and Development
(NIPRD) and commercial partner Xechem. Although its
commercialization experienced difficulties, the case study
highlights the importance of effective leadership and man-
agement, international partnerships, and government
investment, and indicates where challenges might arise.
Firms and institutions focused on commercializing plant
medicines for local or regional markets only are more suc-
cessful; the IMRA (Institut Malgache de Recherches
Appliquées) institution in Madagascar, for example, illus-
trates a decades-old institution that has adapted and scaled
up traditional remedies, though mostly for the local popu-
lace to date.
Local, regional and global dynamics are affecting health
innovation
National institutions, infrastructure and policies set the
basic context for science-based health innovation. How-
ever, our case studies found that regional and global
influences are at least as important in Africa. At a regio-
nal level, access to regional markets is a growing concern
f o rf i r m sa n di ss e e nb ym a n ya st h e‘make or break’ fac-
tor in moving from imitative into innovative activity.
Investing in regional drug-development infrastructure in
order to share costs and centralize expertise was also
cited by firms hoping to manufacture drugs to global
standards. At a global level, South-South partnerships are
playing a key role in technology transfer and capability-
building, particularly in essential medicines [26]. Dia-
spora scientists and managers who are returning to their
countries are often those pushing the boundaries of
health innovation, and bringing with them global con-
tacts and knowledge [27]. International donors strongly
influence a range of areas pertinent to innovation: shap-
ing research agendas, assisting with capacity building in
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Technology Description of technology
(according to the scientist)*
Health
area of application
Country / Institution Status (according to the scientist)
Traditional plant technologies
1 Artemisinin/
lemon grass
combination
A beverage that is used to treat
malaria.
Malaria Uganda- Natural
Chemotherapeutics
Research Laboratory
Ready for commercialization, but not
yet commercialized. Undergoing
clinical trials in northern Uganda
2 Nibima- Extract
of traditional
plant Cryptolepis
sanguinolenta
Whole plant extract for the
management of malaria
Malaria Centre for Scientific
Research into Plant
Medicine, in Mampong,
Ghana http://www.
asnapp.org/
Needs validation through clinical trials
3 Neem tree Extract from the Neem plant Malaria Kenya-ICIPE http://www.
icipe.org
Scientist has no plans to
commercialize. Needs validation
through clinical trials.
4 Neem tree Extract from the Neem plant Malaria Rwanda-IRST http://www.
irst.ac.rw/
Scientist was unsure how to
commercialize. Needs validation
through clinical trials.
5 Whole plant
extract
Whole plant extract Malaria University of Lagos http://
www.unilag.edu.ng/index.
php?page=home
Scientist was unsure how to
commercialize. Needs validation
though clinical trials.
6 Tanzed Plus Whole plant extract for the
management of HIV
HIV/AIDS
management
Tanzania-Muhimbili
University of Health and
Applied Sciences http://
www.muchs.ac.tz
Needs validation through clinical trials
7 Sunguprot Extract of the root of Tylosema
Fassoglensis mixed with soya
beans-Nutritional supplement that
acts as an immune booster.
HIV/AIDS
management
Kenya-KIRDI http://www.
kirdi.go.ke/
Needs validation through clinical trials
8 Morsella A mixture of Moringa oleifera and
hibiscus sabdariffa. Nutritional
supplement that acts as an
immune booster.
HIV/AIDS
management
Tanzania –MUHAS http://
www.muchs.ac.tz/
Needs validation through clinical trials
9 Plants extract Treatment for opportunistic
infections of HIV
Kaposi’s Sarcoma Kenya-KEMRI www.kemri.
org
Applied for patenting. Looking for
commercial investor.
10 Whole plant
extract
Treatment of Fibroids in women Fibroids Kenya- Moi University
http://www.mu.ac.ke/
It is undergoing tests in humans in
the form of pill formulations (Phase 1
clinical trials)
11 Plant extract Has anti-sickling properties which
are attributed to its ability to
prolong or delay the time to
polymerization of deoxy-Hb
Sickle cell anemia
management
Nigeria-NIPRD http://
www.niprd.org/
Orphan drug status by the US Food
and Drug Administration (FDA) and
the European Medicine Evaluation
Agency (EMEA) in 2005. http://www.
highbeam.com/doc/1G1-137075135.
html Limited commercialization but
failed to scale up because of business
failure.
12 Anti-Hepatocyte Plant derivative-A treatment of liver
infections especially liver cirrhosis
Liver ailments Tanzania-NIMR http://
www.nimr.or.tz/
Scientist was unsure how to
commercialize. Needs validation
though clinical trials.
13 Aloe vera
derivatives
Skin ointment Skin ailments Tanzania –MUHAS http://
www.muchs.ac.tz/
Needs validation through clinical trials
14 Aloe vera
derivatives
Skin ointment Skin ailments Rwanda-IRST http://www.
irst.ac.rw/
Scientist was unsure how to
commercialize. Needs validation
through clinical trials.
15 Plant extract Prevents the effects of radiation
during x-ray’s hence preventing
cancers
Anti-radiation Nigeria-University of
Ibadan
Scientist was unsure how to
commercialize. Needs validation
through clinical trials.
16 Mondia Tonic Root of mondia whytei Anti-depressant Kenya-ICIPE http://www.
icipe.org
Partly commercialized. Needs
validation through clinical trials to
scale up commercialization.
Diagnostics
17 Monoclonal
antibody test
for detection of
malaria
A dipstick that uses antibody
antigen reactions to detect
presence of malaria parasites in the
body by testing urine
Malaria Ghana-University of
Ghana http://www.ug.
edu.gh/
Still being developed. Has received
funds from the Gates foundation to
explore the concept further.
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Finally, global regulation – most prominently intellectual
property – continues to shape national policy, with a glo-
bal debate underway on which intellectual property
regimes and incentives will best support research and
innovation in areas such as neglected diseases [28,29].
Therefore, African governments must also be active at
regional and global levels to ensure that local health
needs can be met, including influencing donor policies
to best generate locally-relevant and locally-owned
knowledge.
Institutions used innovative financing mechanisms and
partnerships to their benefit
Our country case studies highlighted the many con-
straints to firms working in health innovation, and
demonstrated how access to financing and to knowledge
through partnerships were key elements to their success.
This was also demonstrated in all six institutional cases.
Means of financing covered a wide spectrum: A to Z
combined co-investment from a Japanese multinational
with its own family funding; Bioventures employed
investment from the International Finance Corporation
and other developmental institutions; the Niprisan pro-
ject gained both private and public funding from Nigeria
and the U.S., as well as indirect financial benefits from
Orphan Drug legislation. Similarly, partnerships played a
key role in each case: IMRA turned its low-resource set-
ting into a strength by playing the role of an authority
on local biodiversity to international researchers;
KEMRI benefited from the Japanese institution JICA as
well as the Wellcome Trust and many research partner-
ships; Acorn’s virtual model used linkages with external
talent to incubate and support its investees. Implications
are that financing and partnerships are key to successful
development of African health solutions; that such
financing and partnerships come in many forms, some
far from obvious; and that supportive platforms that
help enable financing and partnerships, and make such
opportunities clearer to domestic and international
actors, are a cross-cutting means of support that may
benefit all parties. Moves are already being made in this
direction, such as Uganda’s Window C and Presidential
Funds which encourage public-private collaboration.
Linkages between groups are sparse to date, but hold
potential for building stronger health innovation systems
Taking a systemic approach to health innovation in
Africa – i.e examining linkages between groups and
seeking to understand the context affecting health
Table 1 Health technology stagnation in sub-Saharan Africa (Continued)
18 Monoclonal
antibody test
for detection of
Schistosomiasis
Rapid visually read monoclonal
antibody (MoAb) based dipstick
Schistosomiasis Ghana- Noguchi
Memorial Institute for
Medical Research http://
www.noguchimedres.org/
Scientist has not attempted to
commercialize. Ready for
commercialization.
19 ELISA A quick test for identifying MDR TB
in sputum
Tuberculosis Uganda-Makerere
University http://mak.ac.
ug/
No incentive to commercialize hence
no product form developed.
Medical equipment and associated health technologies
20 Medical waste
incinerator
A fuel free medical waste
incinerator. Suitable for destruction
of plastics. Uses medical waste as
fuel by generating very hot gases.
Medical waste Uganda-Makerere
University http://mak.ac.
ug/
WHO approved. Commercialized but
needs scaling up.
21 Female sanitary
towels
Sanitary towels developed from
lemon grass. Cost ¼ of
conventional sanitary towels and
suitable for school girls
Sanitary towels Uganda-Makerere
University http://mak.ac.
ug/
The test was undergoing more
evaluation.
22 Insect repellant Use of human odors to repel
malaria causing mosquitoes
Malaria Kenya-ICIPE http://www.
icipe.org
Patented-Ready for commercialization
but formulation not developed.
23 Insect repellant Plant extract Malaria Tanzania-NIMR http://
www.nimr.or.tz
Needs validation through clinical trials.
24 TBCide Disinfectant. Standardized chlorine
based decontaminant used to
destroy MDR TB.
Tuberculosis.
resistant bacteria on
surfaces bacteria
from hospital
surfaces.
Kenya-KEMRI www.kemri.
org
Patented-Ready for commercial
exploitation
25 Alternative
methodology to
extract and
purify
Artemisinin
To prepare derivatives or combine
it with other anti-malarials to
combat Artemisinin resistance
Malaria Tanzania-NIMR http://
www.nimr.or.tz
Needs extraction equipment and
equipment for further validation
*Scientists interviewed were asked not to disclose any potentially proprietary information. Reprinted from Simiyu, Ken et al. Science; 330: 1483-1484, 10 December 2010.
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for future enquiry. We found a range of institutions and
policies that, on the surface, are relevant to science-
based health innovation in Africa. However, often they
have been modeled on foreign examples and have not
found a natural place within the system, remaining iso-
lated and without function. Relatedly, a range of reasons
such as lack of trust exist for why stakeholders are not
interacting, which need to be addressed if science-based
health innovation is to develop. For example, intellectual
property protection is unlikely to be utilized if firms do
not trust the state to enforce it, and innovation policies
are only valuable if there are means to mobilize stake-
holders around their implementation. On the other
hand, we see that important, organic linkages do exist –
between African firms and other Southern firms,
between firms and consumers, and between universities
and local communities in terms of knowledge transfer
in health – which indicate the beginnings of systemic
interaction which can be built upon. Activities such as
cluster-building in Tanzania, and business incubation in
Uganda and South Africa, illustrate mechanisms that
can bring together business support, mentorship, fund-
ing, and networking to help nascent companies develop
their ideas and business acumen.
Concluding remarks
The research presented in the series highlights compel-
ling examples of African-led health innovation, including
Tanzania’sAt oZ ,N i g e r i a ’s Niprisan, LaGray’sl o c a l
production of Active Pharmaceutical Ingredients, and
several investments in scientifically upgrading plant
medicine. For the most part, these are not ‘world-first’
innovations, but rather Africa-firsts, involving the adop-
tion and adaptation of technologies to become more
affordable, convenient and suitable to African condi-
tions. However some examples, such as the sickle-cell
drug Niprisan, are world firsts.
All of the examples highlight pioneering attempts to
build technological capacity, create economic opportu-
nities, and retain talent on a continent significantly
affected by brain drain. The examples are largely “one-
off’s”, pursued by highly motivated individuals with
generally weak support networks. They point to the
practical challenges for innovators on the ground, and
suggest potentially helpful policies, funding streams, and
other support systems.
Most importantly, perhaps, they illustrate the diversity of
types of health innovation that are occurring in Africa –
each of which utilize different competencies, resources,
and strategies, depending on the technology, the market,
the investment, the source of knowledge, and other fac-
tors. As such, clarifying the best strategies to support
health innovation will be critical to African countries, both
individually and working across regions. Some of these
strategies in the context of investment and market oppor-
tunities for African health innovation have been set out
elsewhere [30]. An area for future research is to develop
an interactive “opportunity guide” with which countries
and institutions can explore appropriate health innovation
opportunities, according to their resources, goals, and
competencies – building on work already underway for
pharmaceutical innovation in Africa [31].
One compelling argument for local innovation relates
to the fact that much of the prevalent disease burden
could be mitigated through locally relevant and afford-
able diagnostics, drugs, and devices, and more generally
through better public health infrastructure and comple-
mentary health delivery systems – all of which are cultu-
rally specific. The value of harnessing local insights, then,
goes beyond keeping profits and capabilities in Africa – it
also has direct potential to customize novel prevention
and treatment methods, so that diseases are addressed at
scale more effectively. Indeed, much of the health innova-
tion chronicled in these papers has come about through
intimate knowledge of local markets, generation of local
health delivery systems, and similar tacit knowledge that
comes from “learning by doing”;s u c h“innovation capi-
tal” may not be captured well by traditional metrics such
as patents and researchers per capita. All of these consid-
erations suggest a uniquely African approach toward
health innovation that may emerge.
A related challenge is moving African health innovation
from a collection of one-off success stories to a set of sus-
tainable innovation systems: KEMRI, Niprisan, and Acorn
are examples of cases illustrating the difficulties involved.
Greater understanding and capacity is needed to under-
stand financial and organization models sustainable in the
long term, and incentives for institutions and policy-
makers to adapt and refine these models. Flexibility to
design such models and create enabling policies will also
be needed, and donors should be cognizant of this. The
Ghanaian attempt to address stimulate microbusinesses
around health needs, which floundered due to lack of
resources and pressures from competing priorities, is a
case in point. Funding is a core requirement for sustain-
ability, and it is worth noting that many of the countries
discussed do have precedents in the form of domestic and
international investment into low-risk health delivery ven-
tures like hospitals. There may be potential to channel
some of this funding to lower-risk R&D, which could
complement venture funding and international health
R&D dollars for earlier-stageo rm o r er i s k yR & D ,e . g .a s
part of product development partnerships.
An important element for success will be devising and
supporting strategies which energize diverse parts of the
innovation system together around specific goals and
r e a l i s t i ca i m s .A ne x a m p l ew o u l db eas t r a t e g yt ob r i n g
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disconnected so far – science, business and capital. We
have proposed the idea of an innovation platform to do
this, combining physical and virtual elements [32,33]. A
network of such platforms could provide a single point
of entry for developmental and private investors inter-
ested in supporting innovation in Africa.
For African nations, health innovation represents an
opportunity to increase domestic capacity to solve
health challenges; for international funders, it is an
opportunity to move beyond foreign aid and depen-
dency. The shared goal is creating self-sustaining inno-
vation that has both health and development impacts.
This is a long-term strategy, and we do not underesti-
mate the difficulties. At the same time, this series shows
the potential of African-led innovation, and indicates
how it might balance realism against opportunity. There
is scope to learn lessons more systematically from cases
like those we discuss; to link entrepreneurs, scientists,
funders, and policy-makers into a network to share
opportunities and challenges; and ultimately to better
support and stimulate African-led health innovation.
At its core, innovation is about taking knowledge and
making it work for a society. African nations may not
be able to reinvent themselves as knowledge economies
overnight. They can, however, take realistic steps in this
direction, while benefiting in both health and economic
terms. External funders and partners, by supporting
African-led innovation, can help to make the influx of
funding more fair, respectful, and sustainable, leading to
greater capacity and autonomy in recipient countries.
Acknowledgements
This series is dedicated to Sara Al-Bader, a brave and brilliant doctoral
student who was dedicated to Africa; tragically, Sara and her husband Mike
died in a car accident on November 20, 2010.
We are grateful to Jocalyn Clark for comments on drafts of the manuscript; to
our colleagues at the McLaughlin-Rotman Centre for Global Health for general
suggestions on this BMC series; and to all those with whom we spoke for their
time and willingness to share experiences. We also thank the peer reviewers of
this supplement for their time, feedback, suggestions, and insights.
This project was funded by Genome Canada through the Ontario Genomics
Institute, and by a grant from the Bill & Melinda Gates Foundation through
the Grand Challenges in Global Health Initiative; it was supported by the
McLaughlin-Rotman Centre for Global Health, an academic centre at the
University Health Network and University of Toronto.
This article has been published as part of BMC International Health and
Human Rights Volume 10 Supplement 1, 2010: Health innovation in sub-
Saharan Africa. The full contents of the supplement are available online at
http://www.biomedcentral.com/1472-698X/10?issue=S1.
Competing interests
The authors declare that they have no competing interests.
Published: 13 December 2010
References
1. Jamison D, Mosley WH, Measham A, Bobadilla JL: World development
report : Investing in health. Washington, DC: World Bank; 1993.
2. The business of healthcare innovation. Cambridge University Press;Burns
LR 2005.
3. Mehta SS: Commercializing Successful Biomedical Technologies: Basic
Principles for the Development of Drugs, Diagnostics and Devices.
Cambridge University Press; 2008.
4. Achilladelis B, Antonakis N: The dynamics of technological innovation: the
case of the pharmaceutical industry. Research Policy 2001, 30:535-588.
5. European Parliament: Report on Major and Neglected Diseases in
Developing Countries. 2005, Brussels.
6. Kettler H, Collins C: Balancing Health Needs and Drug Research
Incentives. Cooperation South Journal 2002, 10-36.
7. Moran M, Ropars A-L, Guzman J, Diaz J, Garrison : The new landscape of
neglected disease drug development. Wellcome Trust: London, UK; 2005.
8. Moran M, Guzman J, Henderson K, Ropars AL, McDonald A, McSherry L,
Wu L, Omune B, Illmer A, Sturm T, Zmudzki F: G-FINDER 2009: Neglected
Disease Research & Development: new times, new trends. The George
Institute for International Health: Sydney, Australia; 2009.
9. Frew SE, Kettler HE, Singer PA: The Indian and Chinese Health
Biotechnology Industries: Potential Champions of Global Health? Health
Affairs 2008, 27(4):1029-1041.
10. Frew SE, Rezaie R, Sammut SM, Ray M, Daar AS, Singer PA: India’s Home-
Grown Health Biotechnology Sector at a Crossroads. Nature Biotechnology
2007, 25(4):403-417.
11. Frew SE, Sammut SM, Shore AF, Ramjist JK, Al-Bader S, Rezaie R, Daar AS,
Singer PA: Chinese health biotech and the billion-patient market. Nature
Biotechnology 2008, 26:37-53.
12. Rezaie R, Frew SE, Sammut SM, Maliakkal MR, Daar AS, Singer PA: Brazilian
health biotech–fostering crosstalk between public and private sectors.
Nature Biotechnology 2008, 26(6):627-644.
13. Gehl Sampath P: India’s Pharmaceutical Sector in 2008: Emerging
Strategies and Local and Global Implications for Access to Medicines.
London, U.K: DFID; 2008.
14. UN Millennium Project 2005: Innovation: applying knowledge in
development. Sterling, VA: Earthscan; 2005.
15. Going for Growth: Science, Technology and Innovation in Africa.
London, U.K.: Report for The Smith Institute;Juma C 2005.
16. NEPAD: Consolidated S&T Action Plan. Pretoria, Republic of South Africa:
NEPAD Office of Science and Technology; 2006.
17. Kalua FA, Awotedu A, Kamwanja LA, Saka JDK: Science, Technology and
Innovation for Public Health in Africa. Pretoria, Republic of South Africa:
NEPAD Office of Science and Technology; 2009.
18. Juma C, Serageldin I: Freedom to Innovate: Biotechnology in Africa’s
Development: Report of the High-Level African Panel on Modern
Biotechnology. Johannesburg, South Africa: African Union and New
Partnership for Africa’s Development; 2007.
19. Nwaka S, Ilunga TB, Da Silva JS, Rial Verde E, Hackley D, De Vré R, Mboya-
Okeyo T, Ridley RG: Developing ANDI: a novel approach to health
product R&D in Africa. PLoS Med. 2010, 7(6):e1000293.
20. Mytelka LK: The Dynamics of Catching Up: The Relevance of an
Innovation System Approach in Africa. In Putting Africa First: The Making of
African Innovation Systems. Aalborg University Press, Aalborg;Mammo
Muchie, Peter Gammeltoft, and Bengt-Åke Lundvall 2003:29-42.
21. Beuzekom B, Arundel A: OECD Biotechnology Statistics 2009. Paris, France:
OECD; 2009.
22. Al-Bader S, Frew SE, Essajee I, Liu VY, Daar AS, Singer PA: Small but
tenacious: South Africa’s health biotech sector. Nature Biotechnology 2009,
27(5):427-445.
23. Freeman C: The ”National System of Innovation” in Historical Perspective.
Cambridge Journal of Economics 1995, 19(1):5-24.
24. National Systems of Innovation: Towards a Theory of Innovation and
Interactive Learning. London, U.K.: Pinter Publishers;Lundvall B.-Å 1992.
25. Government of Ghana: 2010 National Science, Technology and
Innovation Policy. Accra, Ghana: Ministry of Environment, Science and
Technology; 2010.
26. Thorsteinsdóttir H, Melon CC, Ray M, Chakkalackal S, Li M, Cooper JE,
Chadder J, Sáenz TW, de Souza Paula MC, Ke W, Li L, Madkour MA, Aly S,
El-Nikhely N, Chaturvedi S, Konde V, Daar AS, Singer PA: South-South
Entrepreneurial Collaboration in Health Biotech. Nature Biotechnology
2010, 28(5):407-416.
27. Anand NP, Hofman KJ, Glass RI: The globalization of health research:
harnessing the scientific diaspora. Acad Med. 2009, 84(4):525-34.
Al-Bader et al. BMC International Health and Human Rights 2010, 10(Suppl 1):S1
http://www.biomedcentral.com/1472-698X/10/S1/S1
Page 8 of 928. Kyle M, McGahan A: Investments in Pharmaceuticals Before and after
TRIPS. 2009 [http://ssrn.com/abstract=1498969], NBER Working Paper No.
w15468. Available at SSRN.
29. The development agenda: global intellectual property and developing
countries. Oxford; New York: Oxford University Press;Netanel NW 2009.
30. International Finance Corporation: The Business of Health in Africa.
Washington, D.C.: The World Bank Group; 2007.
31. Berger M, Murugi J, Buch E, IJsselmuiden C, Moran M, Guzman J, Devlin M,
Kubata B: Strengthening pharmaceutical innovation in Africa. Council on
Health Research for Development (COHRED); New Partnership for Africa’s
Development (NEPAD); 2010.
32. Al-Bader S, Shah R, Simiyu K, Wiley RE, Kanellis P, Pulandiran M,
Heymann M, Singer PA, Daar AS: Commercializing African Health
Research: Building life science convergence platforms. Global Forum
Update on Research for Health 2008, 5:143-150.
33. Masum H, Daar AS, Al-Bader S, Shah R, Singer PA: Accelerating Health
Product Innovation in sub-Saharan Africa. Innovations 2007, 2:129-149.
doi:10.1186/1472-698X-10-S1-S1
Cite this article as: Al-Bader et al.: Science-based health innovation in
sub-Saharan Africa. BMC International Health and Human Rights 2010
10(Suppl 1):S1.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Al-Bader et al. BMC International Health and Human Rights 2010, 10(Suppl 1):S1
http://www.biomedcentral.com/1472-698X/10/S1/S1
Page 9 of 9